1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Belite Bio, Inc
  6. Summary
    BLTE   US07782B1044

BELITE BIO, INC

(BLTE)
  Report
Delayed Nasdaq  -  04:00 2022-08-10 pm EDT
29.22 USD   +3.54%
08/09BELITE BIO : Receives Approval to Initiate LBS-008 Phase 3 Clinical Trial in Germany
PU
08/08BELITE BIO : Receives Approval of LBS-008 Phase 3 Clinical Trial in Belgium
PU
08/01Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/04/2022 08/05/2022 08/08/2022 08/09/2022 08/10/2022 Date
29.5(c) 30.37(c) 30.02(c) 28.22(c) 29.22 Last
60 181 26 202 60 392 53 125 41 429 Volume
-1.70% +2.95% -1.15% -6.00% +3.54% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -18,9 M - -
Net cash position 2022 29,1 M - -
P/E ratio 2022 -33,0x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -17,8 M - -
Net cash position 2023 8,67 M - -
P/E ratio 2023 -40,9x
Yield 2023 -
Capitalization 727 M 727 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 12
Free-Float 28,5%
More Financials
Company
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration (dry AMD) and autosomal recessive Stargardt disease (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver... 
More about the company
All news about BELITE BIO, INC
08/09BELITE BIO : Receives Approval to Initiate LBS-008 Phase 3 Clinical Trial in Germany
PU
08/08BELITE BIO : Receives Approval of LBS-008 Phase 3 Clinical Trial in Belgium
PU
08/01Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financ..
GL
08/01Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financ..
AQ
08/01HC Wainwright Initiates Coverage on Belite Bio With Buy Rating, $58 Price Target
MT
07/27BELITE BIO : Company Presentation
PU
07/20Belite Bio Seeks FDA Nod For Late-Stage Stargardt Disease Trial; Shares Fall Wednesday
MT
07/20Belite Bio Shares Drop 12% After IND Submitted for LBS-008 Vision Treatment
DJ
07/19BELITE BIO : Submits Investigational New Drug (IND) Application to FDA for Approval to Pro..
PU
07/19Belite Bio Submits Investigational New Drug (IND) Application to FDA for Approval to Pr..
GL
07/19Belite Bio Submits Investigational New Drug (IND) Application to FDA for Approval to Pr..
GL
07/19Belite Bio, Inc Submits Investigational New Drug Application to FDA for Approval to Pro..
CI
07/01Benchmark Capital Initiates Belite Bio at Buy with $57 Price Target
MT
06/24BELITE BIO : announces submission of Clinical Trial Registration for China Phase 3 study o..
PU
06/20BELITE BIO : Receives Approval to Initiate LBS-008 Phase 3 Study at CERA Clinical Trial Si..
PU
More news
News in other languages on BELITE BIO, INC
07/20Belite Bio demande l'aval de la FDA pour un essai de stade avancé sur la maladie de Sta..
07/19Belite Bio, Inc. soumet à la FDA une demande de nouveau médicament de recherche pour ob..
05/05Belite Bio, Inc présente les résultats intermédiaires de l'étude de phase 1b/2 LBS-008 ..
05/03Belite Bio obtient la désignation Fast Track de la FDA pour son médicament candidat con..
05/03Belite Bio reçoit la désignation Fast Track de la FDA pour le LBS-008
More news
Analyst Recommendations on BELITE BIO, INC
More recommendations
Chart BELITE BIO, INC
Duration : Period :
Belite Bio, Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BELITE BIO, INC
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 29,22 $
Average target price 57,50 $
Spread / Average Target 96,8%
EPS Revisions
Managers and Directors
Yue Hsin Lin Chairman & Chief Executive Officer
Hao Yuan Chuang Chief Financial Officer & Director
Nathan L. Mata Chief Scientific Officer
John Michael Longo Independent Director
Yi Ta Lue Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BELITE BIO, INC0.00%702
MODERNA, INC.-31.38%66 950
LONZA GROUP AG-26.76%43 416
IQVIA HOLDINGS INC.-15.05%43 382
SEAGEN INC.13.62%32 387
ALNYLAM PHARMACEUTICALS, INC.36.81%26 810